Enhancing Biomarker Evaluation & Innovating Organoid & AI Models to Test & Validate Patient Samples to Improve Response Rate, Efficacy & Success of Inflammatory Bowel Disease Therapies
Precision medicine is transforming the future of Crohn’s disease and ulcerative colitis. With breakthroughs in AI-driven analytics, multiomic integration, and biomarker-guided therapy design, the field is finally moving beyond symptom management toward truly personalized, durable remission.
Now in its 4th year, the Precision Medicine in Inflammatory Bowel Disease Summit unites 50+ senior leaders across biopharma, translational science, and clinical development to accelerate the next generation of targeted IBD therapies.
This year's agenda explores AI-enabled drug discovery and multiomic use-cases with Takeda, brings exclusive insights from Abbvie and Spyre on combination therapy design, and tackles data challenges with Merck and Crohn’s & Colitis Foundation.
Join leading minds from Johnson & Johnson, Sanofi, Xencor, Astellas, AstraZenecas and more to shape the next era of IBD treatment, where science, strategy, and innovation intersect to deliver smarter, faster, and more effective precision therapies for patients in need.
Attending Companies Include